Search results
Angelman Syndrome Foundation families host third annual awareness walk
KPAX Missoula· 2 days agoThe Missoula County Fairgrounds was filled with a group of angels who braved the elements to raise money and awareness.
Ionis reports positive results for Angelman syndrome drug By Investing.com
Investing.com· 5 days agoIonis Pharmaceuticals, Inc. (NASDAQ:IONS) today shared encouraging topline results from the HALOS...
Ionis, Biogen Down on Ending Development of ALS Drug - Biogen (NASDAQ:BIIB), Heron Therapeutics...
Benzinga· 4 days agoShares of Ionis Pharmaceuticals (NASDAQ: IONS) and Biogen (NASDAQ: BIIB) lost at least 2% in market...
Health Care Roundup: Market Talk
The Wall Street Journal· 5 days agoIonis says ION582 showed consistent improvements across multiple functional domains in a Phase 1/2a study, and that it plans to review...
Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data
FierceBiotech· 5 days agoBiogen’s CEO may have been celebrating “turning a corner” last month, but it looks like the...
Biogen, Ionis shelve ALS drug following study failure
BioPharma Dive via Yahoo Finance· 5 days agoWhile results indicated the drug works as intended, it didn’t have enough of an effect on a protein...
Inhibiting proBDNF to mature BDNF conversion leads to ASD-like phenotypes in vivo - Molecular...
Nature· 3 days agoAutism Spectrum Disorders (ASD) comprise a range of early age-onset neurodevelopment disorders with genetic heterogeneity. Most ASD related genes are involved in synaptic function, which is ...
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $7.00 Consensus PT from Analysts
ETF DAILY NEWS· 1 day agoTaysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) has received an average rating of “Buy” from the nine research firms that are currently covering the company, Marketbeat reports.
Taysha Gene Therapies’ (TSHA) Buy Rating Reiterated at Jefferies Financial Group
ETF DAILY NEWS· 5 days agoTaysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “buy” rating restated by analysts at Jefferies Financial Group in a research note issued on Tuesday, Benzinga reports. Jefferies ...